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Catherine Matte-Martone,1,2 Xiajian Wang,3 Britt Anderson,4 Dhanpat Jain,5
Anthony J. Demetris,6 Jennifer McNiff,7 Mark J. Shlomchik,4,8 Warren D. Shlomchik1,2,8Recipient antigen presenting cells (APCs) are required for CD8-mediated graft-versus-host disease (GVHD),
and have an important and nonredundant role in CD4-mediated GVHD in mouse major histocompatibility
complex-matched allogeneic bone marrow transplantation (alloBMT). However, the precise roles of specific
recipient APCs—dendritic cells, macrophages, and B cells—are not well defined. If recipient B cells are im-
portant APCs they could be depleted with rituximab, an anti-CD20 monoclonal antibody. On the other
hand, B cells can downregulate T cell responses, and consequently, B cell depletion could exacerbate
GVHD. Patients with B cell lymphomas undergo allogeneic hematopoietic stem cell transplantation (alloSCT)
and many are B-cell-deficient because of prior rituximab.We therefore studied the role of recipient B cells in
major histocompatibility complex-matched murine models of CD8- and CD4-mediated GVHD by using re-
cipients genetically deficient in B cells and with antibody-mediated depletion of host B cells. In both CD4- and
CD8-dependent models, B cell-deficient recipients developed clinical and pathologic GVHD. However, al-
though CD8-mediated GVHD was clinically less severe in hosts genetically deficient in B cells, it was unaf-
fected in anti-CD20-treated recipients. These data indicate that recipient B cells are not important
initiators of GVHD, and that efforts to prevent GVHD by APC depletion should focus on other APC subsets.
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Graft-versus-host disease (GVHD) remains a major
toxicity that greatly limits the application and efficacy
of allogeneic stem cell transplantation (alloSCT). Most
patients who undergo alloSCTs receive stem cells from
major histocompatibility complex (MHC)-identical or
matched donors. In these patients, GVHD is initiated
by donor T cells that recognize a subset of host peptides,
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6/j.bbmt.2010.03.015are derived from the expression of polymorphic genes
that differ inhost fromdonor.Wehavepreviously shown
that intact recipient-type antigen presenting cells (APCs)
are absolutely required forGVHDinanMHC-matched,
multiple miHA-mismatched murine model of GVHD
induced only by donor CD81 T cells [1]. In contrast,
either recipient or donor type APCs are sufficient for
CD4-mediated GVHD across only miHAs, although
host APCs are required for a high penetrance of skin
GVHD [2]. In MHC-mismatched GVHD, recipient
APCs have also been shown to be pivotal, and their
depletion by alloreactive natural killer (NK) cells
diminishes GVHD [3,4].
Recipient dendritic cells (DCs), macrophages, and
B cells could theoretically be important APCs for do-
nor T cell priming in alloSCT, and ablation of the ap-
propriate APC subsets could ameliorate GVHD. In
MHCclass I (MHCI) andMHCClass II (MHCII) dis-
parate models of GVHD, add-back of host type B cells
to otherwise GVHD-resistant MHCII2 or donor/
host chimeras did not restore GVHD, whereas splenic
DC partially did so [5]. These experiments addressed
whether host-type B cells are sufficient to promote
GVHD, but did not address their role in a situation
where all other APCs are intact. Add-back
experiments also rely on the correct trafficking of
infused cells, which cannot be assured.Moreover, these
Biol Blood Marrow Transplant 16:1222-1230, 2010 1223B Cells and GVHDexperiments did not address the role of B cells in an
MHC-matched, multiple miHA disparate GVHD
model, akin to the majority of human alloSCTs.
Schulz and colleagues [6] examined the role of re-
cipient and donor B cells in GVHDmediated by a mix
of CD4 and CD8 cells by depleting B cells in neonatal
mice with anti-mu antibodies. Initial T cell priming
was reduced in B cell-depleted recipients; however,
GVHD was not significantly different in B cell-
replete and B cell-depleted hosts. In these experi-
ments, donor cells were also B cell depleted, and thus
potential differences could not specifically be ascribed
to recipient B cells.
B cells are a particularly intriguing target as rituxi-
mab, a humanized monoclonal antibody (mAb) against
human CD20 used to treat CD201 lymphomas, pro-
foundly depletes nonmalignant B cells [7] and has
been efficacious in treating patients with autoimmune
diseases [8]. Recent clinical data also suggests that
rituximab may be efficacious in treating a subset of
patients with chronic GVHD (cGVHD) [9,10],
although in this case rituximab likely targets donor B
cells. The presence of class-switched donor-derived an-
tibodies against miHAs has also correlated with the
presence of cGVHD, suggesting that alloreactive
CD4 cells interact with donor B cells, and it is therefore
reasonable that donor T cells also interact with recipi-
ent B cells [11]. Also, a growing number of patients
with B cell lymphomas now undergo alloSCT, and
most of these will have received rituximab during pri-
mary therapy, as part of the transplant preparative reg-
imen, or both [12,13]. Therefore, it is a clinically
important question to understand the role of recipient
B cells in GVHD.
Recipient B cells should be capable of presenting
self antigen acquired by pinocytosis [14] or by endog-
enous presentation of peptides derived from intracel-
lular proteins [15-18] as well as antigens taken up via
the B cell receptor. B cells can directly activate CD4
cells, which would be a prerequisite for promoting
CD4-mediated GVHD [19-22]. B cells can also
stimulate CD8 cells in vitro [23-25] and their
absence can diminish CD8 responses in vivo [26]. On
the other hand, some CD8 responses are B cell-
independent [26-28] and B cells can even tolerize
CD8 cells [29-31].
To determine if recipient B cells either augment or
suppress GVHD reactions, we compared GVHD in B
cell-replete and B cell-deficient hosts in MHC-
matched, multiple miHA-mismatched models of
CD8- and CD4-dependent GVHD in which host
APCs have essential or nonredundant roles [1,2].
Clinical and pathologic GVHD clearly occurred in
hosts that were genetically deficient in mature B cells
in both models of GVHD. However, CD8-mediated
clinical and histopathologic colon GVHD were less
severe in B cell-deficient hosts, suggesting a potentialrole for host B cells either as APCs or as cells important
for establishing an optimal lymphoid environment for
donor CD81 T cell activation. Alternatively, the ge-
netic deficiency of B cells could have adversely affected
the development of secondary lymphoid tissues,
thereby decreasing the efficiency of donor CD81 T
cell activation [32-34]. To distinguish these, we
depleted B cells in wild-type hosts by treatment with
an antibody against mouse CD20 prior to transplanta-
tion. In these B cell-depleted recipients, both clinical
and pathologic GVHD were indistinguishable from
that in control antibody-treated recipients.MATERIALS AND METHODS
Mice
C3H.SW (H-2b), B10.D2 (H-2d), and B6 muMT
mice (H-2b) [35], which have a targeted disruption of
the membrane exon of the immunoglobulin mu chain
gene and do not have mature B cells, were obtained
from Jackson Labs (Bar Harbor, MA). B6 mice
(H-2b) were obtained from either the Jackson Labs
or from the NCI (Frederick, MD). BALB/c (H-2d)
mice were obtained from the NCI. B cell-deficient
BALB/c JhD mice (.7 generations backcrossed to
BALB/c), homozygous for the absence of all 4 JH
gene segments [36], and thus lacking B cells, were
bred at Yale University. All mice were between 8 and
10 weeks of age.
Cell Purifications
CD8 cells were purified via depletion from lymph
node (LN) cells. LNs were crushed through metal
screens and red cells were lysed using ACK (0.15 M
NH4Cl, 1 mM KHCO3, and 0.1 mM Na2EDTA).
Cells were washed, and LN suspensions were stained
with biotin conjugated antibodies against CD4 (clone
GK1.5, lab grown and conjugated), B220 (clone 6B2;
lab grown and conjugated), and CD11b (clone M1/
70; BD Pharmingen, San Diego, CA). Cells were
washed and then stained with streptavidin-conjugated
magnetic beads (Miltenyi Biotec, Auburn, CA) and
separated on an AutoMACS (Miltenyi Biotec) mag-
netic cell separator. CD8 cells were .90% pure with
CD4 T cell contamination of \2%. Bone marrow
(BM) was flushed from tibias and femurs, followed by
red blood cell (RBC) lysis with ACK. BMwas depleted
of T cells with anti-Thy1.2 conjugated magnetic
microbeads (Miltenyi Biotec) followed by separation
on the AutoMACs or with biotin-conjugated anti-
Thy1.2 (clone 30H12), SA beads and the AutoMACs.
BM Transplantation (BMT)
All transplants were performed according to pro-
tocols approved by the Yale University Institutional
1224 Biol Blood Marrow Transplant 16:1222-1230, 2010C. Matte-Martone et al.Animal Care and Use Committee. B6 and B6 muMT
hosts received 1000 cGy, and were reconstituted with
7  106 C3H.SW T cell-depleted (TCD) BM with
or without 2-3  106 C3H.SW CD81 T cells.
BALB/c and JhD BALB/c hosts received 850-900
cGy, and were reconstituted with 107 unfractionated
spleen cells and 107 TCDBM cells from B10.D2mice.B Cell Depletion
B6 recipients were injected intraperitoneally (i.p.)
with 200 mg of antimouse CD20 (an IgG2ak derivative
of clone 18B12 [37]) or a control IgG2ak derivative of
clone 2B8, the parent antihuman CD20mAb for ritux-
imab (all provided by Marilyn Kehry, Biogen/IDEC,
San Diego, CA). In alloBMT experiments, mice were
treated 2 weeks prior to irradiation.Histologic Analysis
Tissues were fixed in 10% phosphate-buffered for-
malin, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin. Slides were numbered and
read by pathologists expert in skin and gastrointestinal
disease without knowledge as to experimental group.
Skin scoring was as described previously [1,38]. Bowel
and liver GVHD scoring in experiments performed
with muMT and JhD recipients were by D. Jain as
previously described [2,39]. Colon and liver GVHD in
experimentswithanti-CD20 treatment (byA.Demetris)
were assessed as follows. In the liver, portal inflamma-
tion, inflammatory bile duct damage, central perivenuli-
tis, and lobular necroinflammatory activity were
semiquantitatively evaluated on a scale of 0 to 3.
Weighted scores were calculated by multiplying the
portal inflammation and central perivenulitis scores by
a factor of 1. Bile duct injury and lobular necro-
inflammatory activity were multiplied by a factor of
0.5. Total scores for each animal were obtained by add-
ing the weighted scores together. Features evaluated for
colon GVHD included overall inflammation/cryptitis,
average number of apoptotic bodies per 10 crypts in
the most severely affected areas, crypt abscesses, crypt
loss, and ulceration. Each parameter was scored on
a scale of 0 to 3. Weighted scores for each parameter
were calculated as follows: inflammation/cryptitis 0.9;
apoptotic bodies per 10 crypts 0.1; neutrophilic cryp-
titis/crypt abscess 0.4; crypt loss1andulceration 2.
The total score for each animal was derived by adding
together each of the weighted scores.Monitoring of Clinical GVHD
Mice were weighed approximately every 3 days
following BMT. Skin disease was scored in the
C3H.SW/B6 [39] and B10.D2/BALB/c [2] models
as previously described.Statistical Analysis
The significance of differences in weight and clin-
ical disease score were calculated by an unpaired t-test
(one-tailed when comparing BM alone versus T cell
recipients and 2-tailed when comparing wild type
and B cell-deficient T cell recipients). The significance
of differences in GVHD incidence were calculated by
Log Rank using Prism (GraphPad Software, Inc., San
Diego, CA). The significance of differences in histo-
logic score were determined by the Mann-Whitney
test (1-tailed for comparisons between recipients of
BM alone and CD8 cells; 2-tailed for comparisons
between groups that received CD8 cells).RESULTS
Role of B Cells in CD8-Mediated GVHD
To investigate whether recipient B cells are impor-
tant APCs we compared GVHD in wild-type (wt) B6
mice to that in B cell-deficient B6 muMT mice [35].
We utilized the same MHC-matched strain pairing,
C3H.SW (H-2b)/B6 (H-2b), in which we previously
found an essential role for recipient APCs [1]. In each
of 3 independent experiments, muMT recipients of
donor BM and CD8 cells developed less weight loss
than did wt control recipients (Figure 1). Nonetheless,
in 2 of 3 experiments, muMT CD8 recipients devel-
oped significantly more weight loss than did recipients
of only donor BM, indicative of clinical GVHD.
Histologic GVHD was clearly evident in muMT
CD8 recipients. Liver GVHD developed in all 3 repe-
titions and when histopathology scores from the 3 rep-
etitions were analyzed together, relative to BM alone
controls, muMT recipients of CD8 cells had similar
liver involvement as did wt CD8 recipients (P 5
0.08; histopathology scores, Figure 2). Ear GVHD de-
veloped in muMT and wt CD8 recipients in 3 of 3 and
2 of 3 experiments, respectively. When histopathology
scores from the 3 experiments were combined, ear
GVHDwas significant in both muMT and wt CD8 re-
cipients versus BM only controls, yet there was no
difference between the muMT and wt recipients of
CD81 T cells (P 5 .55). In contrast, muMT and wt
CD8 recipients developed colon GVHD in 1 of 3
and 2 of 3 repetitions, respectively. When colon scores
from the 3 repetitions were analyzed together, pathol-
ogy was more severe in wt than in muMT CD8-recip-
ients (P 5 0.03). Significant clinical or histologic
GVHD of nonear skin was not observed in any
experiment (not shown).
In sum, these data unequivocally demonstrate that
recipient B cells are not required for clinical or histo-
logic GVHD in this model. However, clinical
GVHD as measured by weight loss and pathologic co-
lon GVHD was less severe in muMT CD8 recipients,
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Figure 1. muMTrecipients of donor CD8 cells have less weight loss than do wild-type recipients of CD8 cells. Wild-type B6 and B6 muMT mice were
irradiated and reconstituted with TCD C3H.SW BM (5 mice per group) with or without 2-3 106 purified C3H.SWCD81 T cells (13-15 mice/group).
Data are shown from 3 independent experiments. †Indicates days in which P\.05, comparing either B6 or B6 muMT CD8 recipients with the corre-
sponding BM alone group. * Indicates days in which the B6 CD8-recipient group had significantly more weight loss (P\.05) than did the muMT CD8-
recipient group.
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in promoting some aspects of CD8-mediated GVHD.
B cells could directly prime donor CD8 cells or func-
tion as accessory cells that promote the activation
and/or expansion of alloreactive CD8 cells. B cells
also provide immunoglobulin, which has a variety of
immunomodulatory functions. Alternatively, because
B cells contribute to the ontogeny of secondary
lymphoid tissues, reduced GVHD in muMT hosts
could have been because of developmental differences
rather than only the absence of B cells at the time of
transplantation [32-34].
To distinguish these possibilities, we used an mAb
against mouse CD20 to deplete B cells from wt B6 re-
cipients prior to using these mice in GVHD experi-
ments. We first analyzed the efficacy of anti-CD20 in
depleting splenic and LN B cells, as these are the pri-
mary sites for T cell priming in GVHD [40,41]. Mice
were injected with 200 mg of anti-CD20 or an isotype-
matched control antibody that recognizes human and
not mouse CD20. Two weeks postinjection, B cellcolon
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CD20 resulted in 240- and 50-fold reductions in
splenic and LN B cells, respectively (Figure 3A). We
next confirmed that prior treatment with anti-CD20
depleted B cells to a greater degree than did irradiation
alone. Mice were treated with anti-CD20 or control
antibody 2 weeks prior to receiving 1000 cGy.
Twenty-four hours postirradiation, B cells in spleen
and LN were enumerated. The addition of anti-
CD20 prior to irradiation induced a .30-fold further
reduction of splenic and LN B cells than did pretreat-
ment with the control antibody (Figure 3A). Of note,
without anti-CD20 treatment the number of splenic
B cells 24 hours postirradiation is greater than the
number of DCs (mean of 2.7  105 DCs/spleen in
irradiated recipients of isotype-control antibody).
To determine whether reagent-based B cell deple-
tion affects GVHD, anti-CD20- or isotype control-
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1226 Biol Blood Marrow Transplant 16:1222-1230, 2010C. Matte-Martone et al.GVHD development. GVHD in anti-CD20 and
isotype control-treated CD8 recipients was similar as
measured by weight loss (Figure 3B; data combined
from 2 experiments) incidence of skin disease
(Figure 3C; data from the 1 of 2 experiments in which
there was clinical skin disease), and blinded scoring
of histopathology of liver, colon, skin, and ear
(Figure 3D). As anti-CD20 and control-treated CD8recipients developed similar GVHD, it is highly likely
that the diminished GVHD seen in muMT mice was
not because of the absence of host B cells during
priming, but rather because of a developmental
difference, perhaps abnormalities in secondary lym-
phoid organogenesis, or as a consequence of differ-
ences in gut flora secondary to life-long B cell
depletion.
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Figure 4. B cell-deficient JhD BALB/c recipients of donor B10.D2 spleen cells develop GVHD. JhD BALB/c or wild-type BALB/c recipients were irra-
diated and reconstituted with T cell-depleted B10.D2 BM (4 mice/group) without or with 107 B10.D2 spleen cells (10-11 mice per group). Shown are
results from 2 independent experiments. All statistical comparisons are between JhD and wild-type recipients of donor spleen cells. Experiment 1
data are in A, B, and C: incidence of clinical skin disease, A; clinical skin score, B (*P\.03); weight change, C (*P\.03). Experiment 2 data are in D, E,
and F: incidence of clinical skin disease, D (*P\.05); clinical skin score, E (*P\.05 at day 26 only); weight change, F (*P\.006 at all time points beginning
on day117).
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To analyze the role of recipient B cells in CD4-
mediated GVHD we utilized the B10.D2 (H-2d)/
BALB/c (H-2d) CD4-dependent model of cGVHD.
GVHD in this system is manifested by alopecia, skin
fibrosis, salivary, and lacrimal gland involvement, and
mild portal inflammation [38,42]. Disease caused by
unfractionated spleen cells is equivalent to that with
purified CD4 cells, and in our hands CD8 cells do
not induce clinical or histologic GVHD [43]. JhD or
wild-type BALB/c mice were irradiated and reconsti-
tuted with TCD B10.D2 BM with or without 107
B10.D2 splenocytes. In Experiment 1, JhD and wt
spleen cell recipients developed a similar incidence of
clinical cGVHD (Figure 4A). However, the severity
of skin disease in affected JhD recipients was greater
than that in wt mice (Figure 4B), as was weight loss
(Figure 4C). In Experiment 2, both incidence and
skin scores were similar in JhD and wt recipients of
spleen cells (Figure 4D and E), although again JhD
mice had more weight loss (Figure 4F). Both JhD
and wild type recipients of spleen cells developed
skin fibrosis and interface dermatitis typical for this
model (Supplemental Figure 1). Thus, although there
were modest differences in the penetrance of skindisease and the severity of weight loss between the 2 ex-
periments, they both showed that recipient B cells are
not required for GVHD in this CD4 T cell-mediated
model. If anything, their absence may increase the
severity of GVHD.DISCUSSION
These studies clearly demonstrate that recipient B
cells are neither required for nor have a major impact
on GVHD induced by CD41 or CD81 T cells in
2 models for which we have previously established
essential roles for host APCs [1,2]. Nonetheless,
depending on the model, the presence of B cells did
affect the quality and/or severity of GVHD, albeit to
a minor and somewhat variable extent. We observed
unequivocal histologic GVHD in genetically B
cell-deficient recipients of donor CD8 cells. Although
there was some interexperiment variability in the se-
verity of GVHD and pattern of organ involvement,
which is characteristic of GVHD in this model (our
unpublished observations over many experiments), in
individual experiments, histologic GVHD (compared
with recipients of only donor BM) was statistically sig-
nificant in the ear, small bowel, and colon in muMT
1228 Biol Blood Marrow Transplant 16:1222-1230, 2010C. Matte-Martone et al.CD8 recipients, and significant in the liver in all
repetitions. When the combined histology scores
were analyzed, GVHD in both the ear and liver were
similar in both wt and muMT CD8 recipients. Never-
theless, weight loss in muMT CD8 recipients was
significantly less than that in wt CD8 recipients in
2 of 3 repetitions as was overall colon GVHD. To
determine whether the reduction in clinical and path-
ologic GVHD was a consequence of the absence of B
cells at the time of transplant or a consequence of a de-
velopmental defect in secondary LNs because of the
life-long absence of B cells [32-34], or to other
consequences of life-long B cell deficiency, for exam-
ple on commensual flora, we compared GVHD in
mice acutely depleted of B cells using an anti-CD20
mAb [37]. In this case, histologic and clinical GVHD
was similar in anti-CD20 and isotype control-treated
CD8 recipients. Thus, it is likely that the reduction
in clinical and histopathologic colon GVHD observed
in muMT mice was due to a developmental difference
rather than the absence of recipient B cells, which di-
rectly promote alloreactive T cell generation. We do
not know how a life-long absence of B cells specifically
diminished colon GVHD. Perhaps this is a conse-
quence of altered gut flora; alternatively, priming in
mesenteric lymphoid tissues could be more affected
by an absence of B cells.
Our goal was to assure B cell depletion by
anti-CD20.We therefore transplantedmice 2weeks af-
ter antibody injection, althoughB cell depletion can last
3 to 4 weeks. It is therefore possible that there was suf-
ficient residual anti-CD20 to transiently deplete donor-
derived B cells.We point out that donor BM-derived B
cells do not begin to appear until 10 to 14 days post-
transplantation [44,45], making it likely that there
were few donor B cells exposed to anti-CD20. If anti-
CD20 treatment did suppress donor B cells, their addi-
tional depletion did not affect GVHD.
We also found that CD4-mediated GVHD was
intact in B cell-deficient recipients. Indeed, host B cells
may regulate rather than promote GVHD in this
model, as JhD recipients of splenocytes had more
severe cutaneous GVHD in Experiment 1 and greater
weight loss in both experiments compared to wt
recipients of spleen cells.
A regulatory role for B cells has been demonstrated
in murine models of EAE, inflammatory bowel disease
and diabetes. Regulatory B cells have been suggested to
suppress inflammation via a number ofmechanisms, in-
cluding the elaboration of IL-10 and TGF-b and by
acting as a suppressive second-line APC (reviewed in
[46]).More recently,wehave founda role for regulatory
B cells in the nonobese diabetic (NOD)model of diabe-
tes [47].Thus, it is possible that the absence of such cells
in JhD recipients augmented GVHD. In any case, our
data definitively exclude a requirement for recipient B
cells in CD4-mediated GVHD pathogenesis.Hill and colleagues [48] reported that muMT
mice developed more severe GVHD in the fully
MHC-mismatched BALB/c/B6 strain pairing. They
noted that irradiation increased IL-10 mRNA in resid-
ual host B cells, and that GVHD was more severe in
IL-102/2 hosts and in mixed muMT1IL-102/2 BM
chimeric hosts in which most B cells were IL-102/2,
although a fraction of other IL-10-producing cells,
including regulatory T cells, may also have been
Il-102/2. It is possible that we observed more GVHD
in JhD recipients because of a similarmechanism.How-
ever, that the absence of host B cells, by either genetic or
reagent-based approaches, did not increase CD8-
mediated GVHD in the C3H.SW/B6 strain pairing
suggests that host B cell mitigation of GVHD is
model-specific, and perhaps depends on whether CD4
cells are pathogenic.
B cells have a well established role in stimulating
memory, and under certain circumstances, naı¨ve
CD4 cells [19-22]. Therefore, it would not have been
surprising to observe less GVHD in B cell-deficient
hosts. A small retrospective study reported a trend
toward reduced acute GVHD in alloSCT patients
who received rituximab as part of an ablative condi-
tioning regimen for treatment of acute lymphoblastic
leukemia, compared to similarly transplanted patients
who did not receive rituximab [49]. A second retro-
spective study suggested that treatment with rituximab
in the 6 months prior to nonmyeloablative alloSCT
reduced the incidence of extensive cGVHD [50]. In
human studies, Ritz and colleagues [11,51,52] found
a correlation of donor-derived antibodies against an
antigen encoded by the Y chromosome gene DBY in
male recipients of female grafts with cGVHD. Because
these antibodies were IgH class-switched, the B cells
that expressed these B cell receptors must have had
productive encounters with a CD40L1 donor CD4
cell. Consistent with this, a CD4 response against
DBY has been found in a patient with antibody against
DBY [52]. These studies raise the intriguing possibility
that donor B cells might be important APCs for
alloreactive donor CD4 cells. If so, this would be an
elegant explanation for responses of cGVHD patients
to rituximab, despite the minimal role for host B cells
inGVHD induction [9,10]. Oneway of reconciling this
result with our studies is that we assessed the
importance of recipient B cells in priming naı¨ve CD4
cells at the time of transplant whereas Ritz and
colleagues may have revealed a role for B cells
in established cGVHD, wherein they may further
activate CD4 cells that may have been initially primed
by an APC other than a B cell. Also consistent with
this, in a mouse model of cGVHD and nephritis
induced by transferring DBA/2 splenocytes into
sublethally irradiated BALB/c mice, autoantibodies
were donor-derived and skin thickening depended on
donor B cells [53].
Biol Blood Marrow Transplant 16:1222-1230, 2010 1229B Cells and GVHDTaken together, our data indicate that recipient B
cells are not required for the initiation of either CD8
or CD4-mediated GVHD across only minor H
antigens. APC-targeted therapies to prevent GVHD
should target other APC subsets.ACKNOWLEDGMENTS
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